Sec Form 4 Filing - BVCF Management, Ltd. @ Jaguar Animal Health, Inc. - 2015-05-18

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person BVCF Management, Ltd. 2. Issuer Name and Ticker or Trading Symbol Jaguar Animal Health, Inc. [ JAGX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) SUITE 2606, TOWER 1, NEW RICHPORT CENTER, 763 MENGZI ROAD, HUANGPU DISTRICT 3. Date of Earliest Transaction (MM/DD/YY) 05/18/2015 (Street) SHANGHAI, F4200023 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 05/18/2015 C 1,483,326 A 1,522,881 I See Footnote ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 1 ) 05/18/2015 C( 1 ) 2,224,991 ( 1 ) ( 1 ) Common Stock 1,483,326 $ 0 0 I By Kunlun Pharmaceuticals, Ltd. ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other BVCF Management, Ltd. SUITE 2606, TOWER 1, NEW RICHPORT CENTER 763 MENGZI ROAD, HUANGPU DISTRICT SHANGHAI, F4200023 X Kunlun Pharmaceuticals, Ltd. SUITE 2606, TOWER 1, NEW RICHPORT CENTER 763 MENGZI ROAD, HUANGPU DISTRICT SHANGHAI, F4200023 X BVCF III, L.P. SUITE 2606, TOWER 1, NEW RICHPORT CENTER 763 MENGZI ROAD, HUANGPU DISTRICT SHANGHAI, F4200023 X BVCF III-A, L.P. SUITE 2606, TOWER 1, NEW RICHPORT CENTER 763 MENGZI ROAD, HUANGPU DISTRICT SHANGHAI, F4200023 X Signatures /s/ John A. Kallassy, Attorney-in-Fact for BVCF Management, Ltd. 05/18/2015 Signature of Reporting Person Date /s/ John A. Kallassy, Attorney-in-Fact for Kunlun Pharmaceuticals, Ltd. 05/18/2015 Signature of Reporting Person Date /s/ John A. Kallassy, Attorney-in-Fact for BVCF III, L.P. 05/18/2015 Signature of Reporting Person Date /s/ John A. Kallassy, Attorney-in-Fact for BVCF III-A, L.P. 05/18/2015 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These securities automatically converted into Issuer's common stock on a 1.5 to 1 basis immediately prior to the consummation of Issuer's initial public offering ("IPO") and had no expiration date. ( 2 )Represents (i) 39,555 shares held by Sichuan Biopharma ("Sichuan") and (ii) 1,488,326 shares held by Kunlun Pharmaceuticals, Ltd. ("Kunlun"). Sichuan is an investment vehicle of BVCF Management, Ltd. ("BVCF"). Kunlun is directly owned by BVCF III, L.P. and BVCF III-A, L.P. BVCF III, L.P. and BVCF III-A, L.P. are managed by BVCF. Zhi Yang is Chairman, Founder, Managing Partner and sole shareholder of BVCF and may be deemed to have sole voting and dispositive power with respect to the shares held by Sichuan and Kunlun. Zhi Yang disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.